Interest also was shared by cardiologists when the results of the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG-OUTCOME) trial revealed that the SGLT2 inhibitor empagliflozin, compared with standard antidiabetic treatment, reduced cardiovascular mortality and morbidity in type 2 diabetic patients with established cardiovascular disease [4,5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.